EX-23.1 3 tm227465d1_ex23-1.htm EXHIBIT 23.1

 

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

 

We consent to the use of our report dated February 24, 2022, with respect to the financial statements of Edgewise Therapeutics, Inc., incorporated herein by reference.

  

/s/ KPMG LLP

Denver, Colorado

 

February 24, 2022